Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site.
https://seer.cancer.gov/csr/1975_2015
.
2. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25.
3. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B‑cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007;
https://doi.org/10.1002/14651858.cd003805.pub2
.
4. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.
5. Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving Ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;
https://doi.org/10.1093/cid/ciy175
.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Editorial: critical issues in lymphoma management;memo - Magazine of European Medical Oncology;2019-03